Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases

Hepatology Research

Volumn 43, Issue 11, 2013, Pages 1125-1126

  Yoneda, Masato ^a  

^a YOKOHAMA CITY UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL LIVER DISEASE; BODY MASS; CHRONIC LIVER DISEASE; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECHOGRAPHY; EDITORIAL; FATTY LIVER; GOLD STANDARD; HEPATITIS C; HUMAN; JAPANESE; LIVER BIOPSY; MEASUREMENT; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE; OBESITY; PRIORITY JOURNAL; RADIATION EXPOSURE; RIGIDITY; TREATMENT RESPONSE;

EID: 84886859203     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12111     Document Type: Editorial

References (15)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
3. Sanyal AJ, Brunt EM, Kleiner DE etal. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54: 344-353.
4. Negro F, Clément S. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. J Viral Hepat 2009; 16 (10): 681-688.
5. Sanyal AJ, American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-1725.
6. Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology 2001; 33 (1): 196-200.
7. Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 2000; 14: 543-548. Review.
8. Yoneda M, Yoneda M, Fujita K etal. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut 2007; 56: 1330-1331.
9. Yoneda M, Yoneda M, Mawatari H etal. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008; 40: 371-378.
10. Sasso M, Beaugrand M, de Ledinghen V etal. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36: 1825-1835.
11. Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol 2012; 36 (1): 13-20.
12. Myers RP, Pollett A, Kirsch R etal. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012; 32: 902-910.
13. Masaki K, Takaki S, Hyogo H etal. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol Res 2013; 43: 1182-1189.
14. Foucher J, Castéra L, Bernard PH etal. Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol 2006; 18: 411-412.
15. Myers RP, Pomier-Layrargues G, Kirsch R etal. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55 (1): 199-208.